Risk factors for hypogammaglobulinemia after allo-SCT

Arai, Yasuyuki; Yamashita, Kouhei; Mizugishi, Kiyomi; Kondo, Tadakazu; Kitano, Toshiyuki; Hishizawa, Masakatsu; Kadowaki, Norimitsu

doi:10.1038/bmt.2014.28

Cited by 22 publications

(15 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Immune defects are common consequences, persisting for years after ASCT. Arai et al ( 48 ) recently described that the cumulative incidence of hypogammaglobulinemia (IgG < 400 mg/dl) in a cohort of 278 patients was 24.1 or 27.1%, respectively 1 or 3 years after ASCT. Risk factors were lymphoid malignancies, history of previous ASCT, usage of mycophenolate mofetil, low pre-ASCT IgG levels, and grade 2–4 aGVHD.…”

Section: Bone Marrow Transplantationmentioning

confidence: 99%

Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia

et al. 2014

View full text Add to dashboard Cite

Immunoglobulin (Ig) replacement therapy dramatically changed the clinical course of primary hypogammaglobulinemias, significantly reducing the incidence of infectious events. Over the last two decades its use has been extended to secondary antibody deficiencies, particularly those related to hematological disorders as lymphoproliferative diseases (LPDs) and multiple myeloma. In these malignancies, hypogammaglobulinemia can be an intrinsic aspect of the disease or follow chemo-immunotherapy regimens, including anti-CD20 treatment. Other than in LPDs the broadening use of immunotherapy (e.g., rituximab) and immune-suppressive therapy (steroids, sulfasalazine, and mycophenolate mofetil) has extended the occurrence of iatrogenic hypogammaglobulinemia. In particular, in both autoimmune diseases and solid organ transplantation Ig replacement therapy has been shown to reduce the rate of infectious events. Here, we review the existing literature about Ig replacement therapy in secondary hypogammaglobulinemia, with special regard for subcutaneous administration route, a safe, effective, and well-tolerated treatment approach, currently well established in primary immunodeficiencies and secondary hypogammaglobulinemias.

show abstract

Section: Bone Marrow Transplantationmentioning

confidence: 99%

Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia

et al. 2014

View full text Add to dashboard Cite

show abstract

“…It is suspected that most of the patients who experienced long-term episodes of GvHD acquired fatal infection or organ dysfunction after continuous immunosuppressive status due to the nature of the GvHD itself or its treatment. 34,35 Among these patients, the main cause of mortality was recorded as infection or organ failure in our database.…”

Section: © Ferrata Storti Foundationmentioning

confidence: 99%

Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia

et al. 2016

View full text Add to dashboard Cite

“…Patient characteristics and CBT procedures are summarized in Table 1, and definition of transplantation risk and myeloablative conditioning regimens were in accordance with previous studies. 4,5 MMF was orally administered at 10 mg/kg, three times a day (i.e. total dose=30 mg/kg/day) (with the exact intervals of 8 h), from Day 0 to Day 30.…”

mentioning

confidence: 99%